将投中网设为"星标⭐"，第一时间收获最新推送 联想之星投资的早期科技项目正集中兑现，而更多IPO已在途中。 来源丨 投中网 两天时间，联想之星便收获了两个明星IPO。 1月9日，小核酸药物公司瑞博生物（6938.HK）正式登陆港股。一天前，手术机器人公司精锋医疗（2675.HK）在港上市。上市首日开盘，瑞博生物 的股价较发售价57.97港元涨超23%，市值超过118亿港元。 一路走来，瑞博生物不仅获得了联想之星、君联资本等众多投资机构的长期支持，还获得了IDG、华夏基金、大成基金等基石投资者的大力押注。 早在2015年，联想之星便成为瑞博生物最早一批机构股东。最终，他们连投了这家公司两轮，并一直陪伴对方至今。伴随着瑞博生物上市的钟声，这家 早期投资机构又收获了一个明星IPO。 从寒冬坚守到春潮涌动，联想之星的硬科技布局正迎来密集IPO收获期：希迪智驾（3881.HK）、精锋医疗（2675.HK）、瑞博生物（6938.HK）—— 短短三周之内，三家IPO，两大前沿赛道，一份长期主义答卷，这是联想之星长期深耕早期科技投资的集中兑现，而更多IPO已在途中。 一家早期投资机构能取得这样亮眼的成绩，可谓相当少见。 关键 ...

攻克氢储运技术难题，支持企业建设科创平台，大力发展生物医药产业……"十四五"以来，福建加快创 新型省份建设，打造全方位推进高质量发展的"创新引擎"。 氢的储运是制约氢产业发展的"痛点"。福州大学党委常委、副校长江莉龙及其团队针对这一难题，将氨 作为高效储氢载体，率先在国际上开展"氨-氢"绿色能源重大技术攻关。该团队创制出可让氨高效分解 的新型低温催化剂，实现了储氢方式的颠覆性创新。 全球首款兼顾1000公里续航和4C超充特性的磷酸铁锂电池发布，全球首次海上风电无淡化海水直接电 解制氢海试成功……一个个科技创新成果，是福建加快创新型省份建设的有力见证。 "十四五"规划以来，福建聚力推动科技创新和产业创新深度融合，奋力争当高质量发展先行者。福建组 织实施95个省级科技重大专项和"揭榜挂帅"项目，推动新一代锂电池、大型储能、海水制氢等领域实现 重大创新突破，助力宁德时代新能源科技股份有限公司（以下简称"宁德时代"）、福建福光股份有限公 司、福建德尔科技股份有限公司等一批领军企业从这里走向世界。 氢能是世界绿色能源发展的重大战略方向。福建省委、省政府始终高度重视氢能产业的应用与发展。 前瞻布局抢占氢能赛道 早在201 ...

来源：科技日报 攻克氢储运技术难题，支持企业建设科创平台，大力发展生物医药产业……"十四五"以来，福建加快创 新型省份建设，打造全方位推进高质量发展的"创新引擎"。 科技创新平台是推进高水平科技自立自强、推动科技创新与产业创新深度融合的重要载体。 全球首款兼顾1000公里续航和4C超充特性的磷酸铁锂电池发布，全球首次海上风电无淡化海水直接电 解制氢海试成功……一个个科技创新成果，是福建加快创新型省份建设的有力见证。 "十四五"以来，福建聚力推动科技创新和产业创新深度融合，奋力争当高质量发展先行者。福建组织实 施95个省级科技重大专项和"揭榜挂帅"项目，推动新一代锂电池、大型储能、海水制氢等领域实现重大 创新突破，助力宁德时代新能源科技股份有限公司（以下简称"宁德时代"）、福建福光股份有限公司、 福建德尔科技股份有限公司等一批领军企业从这里走向世界。 前瞻布局抢占氢能赛道 氢能是世界绿色能源发展的重大战略方向。福建省委、省政府始终高度重视氢能产业的应用与发展。 早在2019年，福建依托福州大学、厦门大学、中国科学院海西研究院等院校，分别建设清源、嘉庚和闽 都创新实验室，布局氢能产业并开展前瞻研究。2024年3月 ...

生物活性分子与成药性优化全国重点实验室汇聚了150余名固定研究人员。 受访者供图 开栏语 生物医药产业是决定未来竞争力的关键赛道，也是广东省全力打造的万亿级产业集群。然而，从"实验 室"到"临床"，从"获批上市"到"广泛可及"，创新之路依然充满挑战与堵点。为此，南方都市报启动"广 州生物医药产业深调研"，以媒体为桥，以调研为基，深入一线探访产业链关键环节——从上游研发支 撑的华珍猴场，到引领前沿的叶文才教授实验室，再到康方生物、百奥泰、明复乐、麓鹏制药、达博生 物等代表性创新药企。 我们试图描摹一幅真实、立体的产业图景:既有攀登科技高峰的雄心，也直面"进院难"、资本接力、长 周期坚守等现实课题。此次系列调研，不仅是观察与记录，更旨在搭建对话平台、凝聚产业共识、提供 决策参考，发挥媒体智库的公共价值，为推动广州乃至粤港澳大湾区生物医药产业突破瓶颈、行稳致 远，贡献一份深度的思考与助力。 在国家创新药物研发的版图上，广东正成为生物医药产业的前沿热土。这里，一个依托我国深厚的中药 和天然药物底蕴瞄准现代新药前沿的战略科技力量正加速崛起——生物活性分子与成药性优化全国重点 实验室。 作为暨南大学首个全国重点实验室，它 ...

Group 1 - The 13th Plenary Session of the 13th Provincial Committee of the Communist Party of China in Liaoning has set the direction and blueprint for the province's comprehensive revitalization during the 14th Five-Year Plan period [1] - The meeting emphasized that the next five years will be a strategic opportunity period for Liaoning to consolidate and expand advantages, break bottlenecks, and strengthen weaknesses [1][2] - The focus will be on high-quality development, with efforts to achieve effective qualitative improvements and reasonable quantitative growth in the economy [1] Group 2 - Jinzhou aims to attract investment in key industries such as petrochemicals and new materials, targeting the creation of two trillion-level industrial clusters [1][2] - Fuxin is set to enhance its transformation and upgrading capabilities, focusing on clean energy and ecological projects to address development bottlenecks [2] - The optimization of the business environment is recognized as crucial for productivity and competitiveness, serving as a foundation for high-quality development in Liaoning [2] Group 3 - The provincial natural resources system will implement a special action to create the best business environment, providing comprehensive services for enterprises [3] - The transportation system will focus on modernizing infrastructure and enhancing the role of ports in supporting regional revitalization [3] - The development of the marine economy is highlighted as a strategic area, with initiatives to enhance competitiveness and foster growth in this sector [4][5] Group 4 - The low-altitude economy will be developed, with plans to enhance the capabilities of Shenyang Airport and achieve significant passenger throughput targets [5] - Liaoning's universities, such as Shenyang Pharmaceutical University, will leverage their strengths in research and innovation to support the province's high-quality development [5][6] - Companies like China Export & Credit Insurance Corporation and China Grain Reserves Corporation are committed to enhancing their roles in supporting the modern industrial system and ensuring food security [6]

Core Insights - AstraZeneca has officially launched its new Global Strategic R&D Center in Beijing, marking its sixth global center and second in China, as part of a $2.5 billion investment plan aimed at accelerating early drug research into clinical development [1][4] - The establishment of the Beijing center signifies AstraZeneca's deeper integration into the local pharmaceutical innovation ecosystem, with plans to increase its workforce in Beijing to approximately 1,700 employees [1][4] Investment and Collaboration - The Beijing center will leverage advanced AI and data science capabilities to enhance drug discovery and clinical development, collaborating with local clinical trial institutions, universities, and biotech companies [4][5] - AstraZeneca has initiated multiple collaborations, including partnerships with Cambridge University and local government bodies, to foster innovation and accelerate drug development [5][6] Strategic Importance of China - Since entering the Chinese market in 1993, AstraZeneca has invested over $5 billion and views China as a critical market, focusing on high-demand therapeutic areas such as oncology and cardiovascular diseases [6][7] - The company has a robust pipeline in China, with over 200 projects and plans to launch 20 global innovative drugs by the end of 2030 [7][8] Clinical Research and Innovation - AstraZeneca has established significant partnerships with nearly 500 hospitals across China, conducting over 160 clinical projects, with a focus on early-stage research [8][14] - The company is actively involved in developing new treatments for chronic diseases and cancer, including the establishment of specialized centers for gastric and lung cancer [8][15] Health Ecosystem Development - AstraZeneca is committed to building a comprehensive health management system that enhances diagnosis, treatment, and management of diseases, aiming to improve healthcare accessibility and quality [15][16] - The company has launched initiatives to train healthcare professionals in remote areas, enhancing local medical capabilities and promoting equitable healthcare access [16]

Core Insights - Shanghai's biopharmaceutical industry is experiencing significant growth, with the scale projected to increase from 761.714 billion yuan in 2021 to 984.702 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 8.94% [1] - The biopharmaceutical manufacturing output is expected to rise from 171.2 billion yuan in 2021 to 201.167 billion yuan by 2024, with a CAGR of 6.9% [1] - By the end of 2024, Shanghai is anticipated to have 2,183 biopharmaceutical enterprises, covering various sectors including manufacturing, services, and wholesale [1] - Shanghai is home to 19 of the top 20 global pharmaceutical companies and 19 of the top 20 medical device companies, which have established headquarters, production, or R&D centers in the city [1] Industry Development Plans - According to the "14th Five-Year Plan" for the development of Shanghai's biopharmaceutical industry, the city aims to establish a world-class biopharmaceutical industry cluster by 2025, including six industrial parks with over 100 billion yuan in scale [2] - In 2022, Shanghai's three leading industries reached a combined scale of 1.8 trillion yuan, with the biopharmaceutical sector accounting for a significant portion [2] - Shanghai has developed a complete biopharmaceutical industry chain with over 80,000 upstream and downstream enterprises, leading the nation with more than 30 companies listed on the Sci-Tech Innovation Board [2] Innovation and Market Position - In 2024, Shanghai is set to approve seven Class I innovative drugs and 15 Class III innovative medical devices, representing 17.5% and 32.6% of the national total, respectively [2] - The city has seen 15 projects with overseas licensing transactions exceeding 500 million USD, with a total transaction value of 19.83 billion USD, marking a 30.5% year-on-year increase and ranking first in the country [2] - Shanghai is positioned to further advance its biopharmaceutical industry amidst a global restructuring phase, focusing on enhancing the entire chain from basic research to application [2]

Core Insights - The Shanghai biopharmaceutical industry is projected to grow from 761.71 billion yuan in 2021 to 984.70 billion yuan by 2024, with an average annual growth rate of 8.94% [1] - The biopharmaceutical manufacturing output is expected to increase from 171.20 billion yuan in 2021 to 201.17 billion yuan in 2024, reflecting a compound annual growth rate of 6.9% [1] - By the end of 2024, Shanghai will have 2,183 biopharmaceutical enterprises, with 19 of the top 20 global pharmaceutical and medical device companies having established headquarters or centers in the city [1] Industry Growth and Development - Shanghai has been a pioneer in the biopharmaceutical sector since 1993, emphasizing modern biotechnology and pharmaceuticals as key high-tech industries [2] - The "14th Five-Year Plan" for Shanghai aims to double the scale of three leading industries, including biopharmaceuticals, with a total fund of 100 billion yuan allocated for these sectors [2] - The biopharmaceutical industry accounted for a significant portion of the 1.8 trillion yuan combined scale of Shanghai's three leading industries in the previous year [3] Innovation and Market Position - Shanghai has established a complete biopharmaceutical industry chain with over 80,000 related enterprises, leading the nation with 30 companies listed on the Sci-Tech Innovation Board [4] - In 2024, Shanghai approved 7 first-class innovative drugs and 15 third-class innovative medical devices, representing 17.5% and 32.6% of the national total, respectively [4] - The city also leads in overseas licensing transactions, with 15 projects exceeding 500 million USD, totaling 19.83 billion USD, marking a 30.5% year-on-year increase [4] Future Prospects - Shanghai is on the verge of surpassing the 1 trillion yuan mark in its biopharmaceutical industry, with plans to enhance the entire value chain from basic research to application [5] - The city aims to become a world-class biopharmaceutical innovation hub and industrial cluster, focusing on accelerating technological innovation and high-end industry leadership [5]

Core Points - The event titled "Socialism is Achieved Through Hard Work, and the New Era is Built Through Struggle" was launched on September 18, featuring the establishment of the "Capital Industry Frontline Science and Technology Talent Lecture Group" [1] - A total of 36 frontline science and technology talents from 12 fields were selected to join the lecture group, showcasing their contributions to modernization in various industries [1] - The series of lectures will integrate policy interpretation with practical sharing, combining efforts from both leaders and technology talents [1] Summary by Categories Event Overview - The launch ceremony took place at the University of Chinese Academy of Sciences on September 18 [1] - The initiative is organized by the Beijing Municipal Committee for Education, Science, and Technology Talent Work [1] Participants and Structure - The lecture group consists of 36 members selected from 12 different fields, including integrated circuits, artificial intelligence, and biomedicine [1] - The format of the lectures will feature a collaboration between leaders and technology talents, enhancing the educational experience [1] Future Plans - Over the next two months, the lecture group will visit 21 universities, including Peking University and Tsinghua University [1]

Core Insights - Beijing's economic and social development is being propelled by the commencement of several key projects, including the South Extension of Line 6, the Second Experimental School, and the Shunyi Regional Medical Center [1] Infrastructure Development - The South Extension of Line 6, located in Tongzhou District, has a total investment of approximately 1.24 billion and spans about 2.1 kilometers with one station, enhancing transportation services in the urban sub-center [2] - The 17th Line, a major north-south transit line, is nearly 50 kilometers long and will achieve full connectivity upon completion of its middle section, reducing travel time from Jiahuai Lake Station to Future Science City North Station to just 66 minutes [2] - The 18th Line, which runs through Haidian and Changping districts, will improve access for commuters in the Beijng area to key employment zones [2] Educational Initiatives - The Second Experimental School in Miyun District has commenced construction with a total investment of about 530 million, covering an area of approximately 75,000 square meters and accommodating 66 classes, addressing enrollment challenges in the surrounding areas [5] Healthcare Projects - The Shunyi Regional Medical Center, with a total investment of around 780 million and a construction area of about 82,000 square meters, aims to enhance healthcare facilities in the region [8] - The Beijing BOE Hospital project has achieved structural completion ahead of schedule, with a total investment of approximately 5.3 billion and a construction area of about 220,000 square meters, positioning it as a regional medical service center [11][13] Urban Development - The China-Germany Industrial Park's landscaping enhancement project has begun, covering approximately 667,000 square meters, aimed at improving the park's attractiveness and capacity [10] - The overall progress of the suburban railway urban sub-center line enhancement project has surpassed 60%, with expectations for completion by the end of the year [2]